Seventh Circuit urged to review AbbVie antitrust ruling
15-10-2020
Pay-for-delay settlements fall for second year: FTC report
06-11-2017
Piotr Swat / Shutterstock.com
The US Federal Trade Commission (FTC) concluded a ten-year pay-for-delay suit yesterday, with AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Federal Trade Commission, FTC, pharmaceuticals, pay-for-delay, US Supreme Court, settlement, Actavis, AbbVie, generics, reverse payments, AndroGel
